Evidence map›Paper›PMID 41721193›Full record

Observational studyInternational journal of hematology2026

Prospective observational study to assess the prognosis of patients with myeloproliferative neoplasms in Japan (MPN-15): results of baseline analysis.

Katsuto Takenaka, Tomoki Ito, Norio Komatsu, Hiroki Yamaguchi, Keita Kirito, Akihiro Tomita, Tomiteru Togano, Takayuki Tanaka, Yuka Sugimoto, Kazunori Murai and 21 more

Abstract readObservational StudyMulticenter Study
PubMed Publisher
In one paragraph

Observational study in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Katsuto TakenakaDepartment of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Ehime, 791-0295, Japan. takenaka.katsuto.hy@ehime-u.ac.jp.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Osaka, Japan.
Norio KomatsuDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Hiroki YamaguchiDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Keita KiritoDepartment of Hematology and Oncology, University of Yamanashi, Yamanashi, Japan.
Akihiro TomitaDepartment of Hematology, Fujita Health University School of Medicine, Aichi, Japan.
Tomiteru ToganoDepartment of Hematology, Shonan Kamakura General Hospital, Kanagawa, Japan.
Takayuki TanakaDepartment of Hematology, Tottori Prefectural Central Hospital, Tottori, Japan.
Yuka SugimotoDepartment of Hematology and Oncology, Mie University Graduate School of Medicine, Mie, Japan.
Kazunori MuraiDepartment of Hematology, Iwate Prefectural Central Hospital, Iwate, Japan.
Hideho WadaDepartment of Hematology, Kawasaki Medical School, Okayama, Japan.
Toshiro KurokawaDepartment of Hematology, Toyama Red Cross Hospital, Toyama, Japan.
Michiaki KoikeDepartment of Hematology, Juntendo University Shizuoka Hospital, Shizuoka, Japan.
Akihiko GotohDepartment of Hematology, Tokyo Medical University, Tokyo, Japan.
Takaaki MaekawaDivision of Palliative Care, National Defense Medical College Hospital, Saitama, Japan.
Yoko KubukiDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Tomoaki AkagiDepartment of Hematology, Aomori Prefectural Central Hospital, Aomori, Japan.
Takuji YamauchiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Yoko EdahiroDepartment of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
Kazuhiko IkedaDepartment of Blood Transfusion and Transplantation Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan.
Toshinori KondoDepartment of Hematology, Kawasaki Medical School, Okayama, Japan.
Hirokazu TanakaTransfusion and Cellular Therapy Center, Kindai University Hospital, Osaka, Japan.
Yasushi MiyazakiDepartment of Hematology, Atomic Bomb Disease Institute, Nagasaki University, Nagasaki, Japan.
Toshiki I SaitoClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Kazuya ShimodaDivision of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, University of Miyazaki, Miyazaki, Japan.
Akiko KadaClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Akiko M SaitoClinical Research Center, NHO Nagoya Medical Center, Aichi, Japan.
Hitoshi KiyoiDepartment of Hematology and Oncology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Koichi AkashiDepartment of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan.
Akifumi TakaoriDepartment of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myeloproliferative neoplasms (MPNs) are clonal hematologic disorders characterized by proliferation of one or more myeloid lineages. Data from large-scale prospective studies in Japan remain limited. We conducted a multicenter, prospective observational study (MPN-15) for the Japanese Society of Hematology to assess clinical characteristics, mutation profiles, risk stratification, and treatment patterns of patients diagnosed with polycythemia vera (PV), essential thrombocythemia (ET), prefibrotic primary myelofibrosis (pre-PMF), and fibrotic PMF after 2016. A total of 1252 patients were enrolled (PV: 323; ET: 726; MF: 203). JAK2V617F mutations were detected in 96.8% of PV patients and approximately 60% of patients with other subtypes; CALR and MPL mutations were more common in ET, pre-PMF, and fibrotic PMF. Chromosomal abnormalities and symptom burden were highest in fibrotic PMF. Thrombotic and survival risk stratification revealed that most patients with PV and ET were high risk. Use of ruxolitinib was reported in 14% of PV and 34% of fibrotic PMF patients, with no serious adverse events. This study represents the first large-scale prospective MPN registry in Japan. Ongoing follow-up will provide critical insights into long-term outcomes and therapeutic optimization in the Japanese population.

Indexed as

Myeloproliferative DisordersAdultAgedAged, 80 and overCalreticulinFemaleHumansJanus Kinase 2JapanMaleMiddle AgedMutationNitrilesPrimary MyelofibrosisPrognosisProspective StudiesCalreticulinCALR protein, humanJAK2 protein, humanJanus Kinase 2MPL protein, humanNitrilesPyrazolesPyrimidinesReceptors, ThrombopoietinruxolitinibBaseline analysisMyeloproliferative neoplasmsProspective survey

Identifiers

PMID41721193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.